Tetrahydroxylated bile acids prevents malignant progression of Barret esophagus in vitro by inhibiting the interleukin-1β-nuclear factor kappa-B pathway

Figure 7 Effect of deoxycholic acid and tetrahydroxylated bile acids co-exposure on interleukin-1β-nuclear factor kappa-B pathway activity in adult tissue-resident stem cells isolated from Barrett esophagus clinical biopsies. Representative immunoblots demonstrating effects of deoxycholic acid (DCA) and tetrahydroxylated bile acids (THBA) co-exposure on interleukin-1β (IL-1β)-nuclear factor kappa-B (NF-κB) pathway activity in Barrett esophagus clinical biopsies (BE-ASCs). A: Cells treated with 100 μM DCA showed significant 2-fold increase of IL-1β protein expression in comparison to untreated cells. THBA and DCA co-exposure resulted in significant decrease of IL-1β expression vs DCA alone; B: Expression levels of IL-1β in BE-ASCs treated with 100 μM DCA, 2000 μM THBA and their combination-2000 μM THBA/100 μM DCA, were correlated with density levels measured by using ImageJ software; C: BE-ASCs treated with DCA demonstrated significant higher level of NF-κB phosphorylation in comparison to untreated cells and treated with combination THBA/DCA, THBA; D: Expression levels of NF-κB in BE-ASCs treated with 100 μM DCA, 2000 μM THBA and their combination-2000 μM THBA/100 μM DCA, were correlated with density levels measured by using ImageJ software. Data are presented as mean ± SD (n = 3). ^aP < 0.05. ^bP < 0.01. IL: Interleukin; DCA: Deoxycholic acid; THBA: Tetrahydroxylated bile acids; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; NF-κB: Nuclear factor kappa-B.